An emerging oral medication could potentially outpace the injectable diabetes drug Ozempic in producing weight loss results, according to recent research studies. The focus of this development encapsulates the exploration of more efficient and less invasive methods for controlling blood sugar levels and managing weight in patients with type 2 diabetes.
Ozempic, generically known as semaglutide, has been widely acknowledged by the medical community for its proven effectiveness in blood sugar control and associated weight loss. However, the existing administration mode, as an injectable once-weekly medication, has been perceived as a limiting factor by some patients and healthcare providers alike.
The new semaglutide pill, presently undergoing clinical trials, promises to be a less invasive and less burdening alternative to the injectable format. Moreover, early research indicates it may even surpass Ozempic in terms of weight reduction outcomes.
These findings have been brought to light through ongoing investigations by the pharmaceutical company Novo Nordisk, the manufacturer of both Ozempic and the investigational semaglutide pill.
In a recently released 68-week study involving 1,961 adults with overweight or obesity, subjects who took the highest dose of 2.4mg semaglutide pill reportedly lost an average of 14.9% of their body weight. Contrastingly, previous clinical trials involving injecting Ozempic showed a weight loss average of around 6.5%.
Given the connection between obesity and type 2 diabetes, this substantial differential in weight loss results potentially holds significant implications. Dr. Robert Kushner, a professor at Northwestern University Feinberg School of Medicine, highlighted the importance of these findings. “The oral semaglutide pill is not just about weight loss, but also about reducing the health risks associated with carrying excess weight,” he emphasized.
“People who carry significant extra weight endure not only societal prejudice and discrimination but also increased risks for a myriad of serious diseases, including diabetes. So with the potential of more than double the weight loss than the injectable, the oral pill could be game-changer,” Dr. Kushner added.
The semaglutide pill has shown to be generally well tolerated by users, with common side effects similar to those found with injectable semaglutide. Those side effects typically include nausea, diarrhea, and other gastrointestinal issues that tend to resolve over time.
Both the injectable and oral versions of semaglutide function by imitating an intestinal hormone that induces feelings of satiety, reducing overall appetite and thereby leading to weight loss.
While it’s crucial to highlight that all results are tentative as regulatory approval is still pending, the overall tone of online responses has been one of excitement and optimism. Health and wellness forums, patient discussion platforms, and social media health-focused communities echo the shared hope that this potential oral alternative will transform the landscape for type 2 diabetes and obesity management.
Consultants have pointed out, however, that the process remains in a relatively early stage, and it will likely be some time before the pill enters mainstream use. It is yet to be determined how the oral semaglutide variant will be priced compared to the established injectable version and how this will impact patient accessibility.
Patients and doctors await the final FDA decision to understand whether these promising results will transition into a real-world positive impact. If approved, the oral semaglutide pill could potentially revolutionize treatment protocols for type 2 diabetes and overweight patients, offering substantial weight loss benefits with simpler administration.
Original Source: https://www.sciencealert.com/oral-alternative-to-ozempic-may-be-even-more-effective-for-weight-loss
